CAS NO: | 2220162-06-9 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
Cas No. | 2220162-06-9 |
别名 | 2,2,2-三氟-N-(丙-2-炔-1-基)乙酰胺 |
Canonical SMILES | O=C(NCCC1=CC=C(O)C=C1)C2CCC3=NC4=CC=C(Br)C=C4CN32 |
分子式 | C20H20BrN3O2 |
分子量 | 414.3 |
溶解度 | DMSO : 5 mg/mL (12.07 mM);Water :< 0.1 mg/mL (insoluble) |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | NMDAR antagonist 1 is a potent and orally bioavailable NR2B-selective NMDAR antagonist[1]. NMDAR antagonist 1 (Compound 5q) exhibits excellent neuroprotective activity[1]. NMDAR antagonist 1 can attenuate Ca2+ influx induced by NMDA[1].NMDAR antagonist 1 can suppress the NR2B up-regulation and increase p-ERK1/2 expression[1].NMDAR antagonist 1 inhibits SH-SY5Y cells with cell viabilities of 75.8%, 80.0%, 84.4%, and 78.6% at 0.1 µM 1 µM 10 µM 100 µM, respectively[1]. [1]. Zhang L, et al. Design, synthesis and bioevaluation of 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxylic acid derivatives as potent neuroprotective agents. Eur J Med Chem. 2018 May 10;151:27-38. |